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Summary 
Plasma membrane transporters, located in the presynaptic terminal and/or surrounding 
glial cells, terminate synaptic transmission by operating rapid, high affinity uptake of 
the neurotransmitter from the synaptic cleft. Pharmacological blockade of transporters 
increases extracellular neurotransmitter levels and prolongs transmitter exposure to the 
receptors. GABA transporters (GATs) belong to the Na
+
 and Cl
-
-dependent transporter 
family. Four GATs have been isolated and cloned in mammals. Of them, GAT-1 and 
GAT-3 are expressed in the retina. GAT-1 has a widespread distribution to different 
retinal cell types, but it is prominently expressed in amacrine cells of all vertebrate 
species studied to date. There are some species differences in the expression patterns of 
GAT-1 in the retina. It is expressed by horizontal cells in non-mammalian but not in 
mammalian retinas, and it is expressed in Müller glial cells of rats and guinea pigs, but 
not of  rabbits and primates. 
Functionally, GAT-1, together with GAT-3, regulates the extracellular GABA levels in 
the retina, thereby determining the level of inhibitory interactions and affecting visual 
processing in the retinal pathways. GAT-1 may interact with GABAC receptors on 
bipolar cell terminals and influence ganglion cell responses. It may also interact with 
GABAB receptors in the regulation of retinal waves of spontaneous activity which are 
known to play critical roles during development of the visual system. Other important 
functional actions are exerted by GAT-1 through reversed GABA transport. These 
include GABA release by cholinergic/GABAergic starburst amacrine cells and GABA 
release during early retinal development. 
Keywords: horizontal cells, amacrine cells, ganglion cells, Müller cells, GABA 
receptors, GABA uptake, reversed transport, retinal development. 
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1. Neurotransmitter transporters 
 
Chemical neurotransmission is a highly complex process which involves release of 
neurotransmitter from the presynaptic terminal, diffusion across the synaptic cleft, and 
binding to receptors on the postsynaptic membrane, resulting in a response of the 
postsynaptic neuron. Overall, neurotransmitter transporters can be classified as 
intracellular vesicular transporters, which are responsible for sequestering transmitters 
from the cytoplasm into synaptic vesicles, and plasma membrane transporters, located 
in the presynaptic terminal and/or surrounding glial cells, which terminate synaptic 
transmission by operating rapid, high affinity uptake of the neurotransmitter from the 
synaptic cleft (1). The transmembrane transport of neurotransmitters is of fundamental 
importance for proper signaling between neurons, as it exerts a key role in controlling 
the neurotransmitter concentration in the synaptic cleft. 
Plasma membrane transporters have long been recognized as important components 
of the machinery for neural signaling. Reuptake inhibitors increase the levels of 
neurotransmitter in the synapse, thus enhancing synaptic transmission, and provide 
important targets for therapeutic intervention. Indeed, the importance of 
neurotransmitter transporters is highlighted by the broad spectrum of drugs targeting 
these proteins, including those used to treat depression, anxiety, obesity and epilepsy, in 
addition to drugs of abuse, such as cocaine, amphetamine and ‘ecstasy’ (2). 
Furthermore, it is well established that neurotransmitter transporters have roles in 
several neurological and psychiatric diseases, including amyotrophic lateral sclerosis, 
severe orthostatic hypotension, obsessive–compulsive disorder, Asperger’s syndrome, 
anorexia and autism (3). 
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Cloning studies show that two distinct gene families encode neurotransmitter 
transporters. One family codes for the high-affinity glutamate transporters (SLC1 gene 
family), the other codes for the Na
+
 and Cl
-
-coupled transporters (SLC6 gene family). 
The latter subclass is the largest and includes transporters of dopamine, serotonin, 
norepinephrine, glycine and GABA (3). Additional proteins may associate with 
transporters in native systems. Indeed, transporters, similar to receptors and ion 
channels, are likely to be associated with other proteins that are necessary for their 
localization near the sites of transmitter release and/or for regulation of transporter 
function (4). 
Important functions of plasma membrane transporters not only include the 
termination of the signaling process by neurotransmitter reuptake, but also 
replenishment of the neurotransmitter supply inside nerve terminals and, in the case of 
the glutamate transporters, keeping the extracellular concentration of glutamate below 
neurotoxic levels. In addition, following membrane depolarization, they can also work 
in reversed mode and mediate nonvesicular, Ca
2+
-independent transmitter release from 
presynaptic terminals (5). Transmitter release by reversed transport can be modulated 
by other neurotransmitters. For instance, both GABA and glutamate may reciprocally 
influence their releases through plasma membrane transporters (6). 
 
2. GABA transporters 
 
In a GABAergic synapse, about 80% of the released GABA is likely to be transported 
back into the GABAergic nerve ending, while the remaining 20% is taken up by the 
astrocytes surrounding the synapse. GABA transporters (GATs) belong to the Na
+
 and 
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Cl
-
-dependent transporter family, composed of several subfamilies including the 
choline, monoamine, taurine, glycine, and betaine amino acid transporters. Most of 
these proteins are made up of approximately 600 amino acid residues, and display a 
molecular mass of around 80 kDa. Some of these transporter subfamilies show a 
common structural organization, characterized by 12 transmembrane segments, 
organized in dimers. A typical conserved feature is the wide extracellular loop localized 
between segments 2 and 4. This structure acts as a site for glycosilation, important for 
the final stage of the insertion of transporters in the plasma membrane (7). These 
proteins also contain three sites of phosphorylation through protein kinase C, and one 
through protein kinase A, likely acting in the functional regulation of the transporter. 
Both the N- and C-terminal regions are located in the cytosol (8). 
The mechanism of the Na
+
 and Cl
-
-dependent transport is complex, and it depends 
on ion cotransport directed by electrochemical gradients. GABA transport is 
electrogenic with a stoichiometry for Na
+
:Cl
-
:GABA transport of 2:1:1 (all inwards). In 
the presence of membrane depolarization and of appropriate gradients, reversed 
transport of GABA may occur (5, 9). GATs are influenced by a variety of physiological 
stimuli, including GABA (10), brain derived neurotrophic factor (11) and hormones 
(12), and they are regulated by multiple intracellular effectors including protein kinase 
C and syntaxin 1A (4, 10, 11, 13). 
To date, three GATs and a betaine glycine transporter (BGT), which also transports 
GABA with high affinity, have been isolated and cloned in mammals (14). 
Unfortunately, different nomenclatures have been used for the GAT subtypes in the 
mouse and in the rat and human, and the resulting picture is rather misleading. GAT1, 
GAT2, GAT3 and GAT4 in the mouse nomenclature correspond to GAT-1, BGT-1, 
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GAT-2 and GAT-3, respectively, in the rat and human nomenclatures (15). The 
rat/human nomenclature will be used in this chapter. 
GAT-1 is considered a ‘neuronal’ transporter, while GAT-2 and GAT-3 are believed 
to be ‘glial’ transporters. The role of BGT-1 in GABA uptake in the brain is not well 
understood (16). GAT-1 is the most widely expressed GAT in the central nervous 
system, mainly localized to presynaptic axon terminals forming symmetric synaptic 
contacts, and to few astrocytic processes. GAT2 is weakly expressed throughout the 
brain, however it is primarily present in the leptomeninges and in ependymal and 
choroid plexus cells and only to a minor extent in neuronal and non-neuronal elements. 
GAT-3 is almost exclusively localized to distal astrocytic processes (14). 
A number of inhibitors of GABA transport have been discovered (17). At least two 
high affinity systems were first identified based on the effects of the GABA uptake 
inhibitors cis-3-aminocyclohexanecarboxylic acid (ACHC) and β-alanine. In particular, 
ACHC, but not β-alanine, strongly inhibits GABA uptake by GAT-1. ACHC inhibition 
is considered a typical property of neuronal transporters. In contrast, GABA uptake by 
GAT-2 and GAT-3 is strongly inhibited by β-alanine, but not by ACHC, which is 
considered a property of glial transporters (14). BGT-1 is competitively inhibited by 
betaine (18). Nipecotic acid and guvacine, two additional inhibitors of GABA transport, 
served as lead structures for the synthesis of a series of selective, high-affinity GAT-1 
inhibitors, such as tiagabine, which penetrate the blood–brain barrier (19). Some of the 
main characteristics of GATs are reported in Table 1. 
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3. The GABAergic system in the retina 
 
GABA is the major inhibitory neurotransmitter in the retina. Inhibitory signaling 
pathways play a fundamental role in the shaping of visual information by modulating 
the flow of visual inputs from photoreceptors to bipolar cells and, subsequently, from 
bipolar cells to ganglion cells. The initial inhibitory interactions in the outer plexiform 
layer (OPL) are mediated by horizontal cells, while those in the inner plexiform layer 
(IPL) are mediated by amacrine cells (Fig. 1). Although the possibility of horizontal 
cell-cone photoreceptor interactions is plausible in mostly non-mammalian retinas (see 
(20) for review), generally GABA does not seem to contribute to lateral inhibitory 
interactions in the OPL (21-23). It is well established, instead, that GABA mediates the 
lateral inhibitory phenomena in the IPL, which contribute to the surround of ganglion 
cell receptive fields (24, 25). The GABA-mediated inhibition in the IPL may also be 
involved in the temporal responses of ganglion cells (26) and plays a fundamental role 
in ganglion cell motion and direction sensitivity (27). Recent papers have reviewed the 
localization patterns of GABA and its receptors as well as the physiology of the 
inhibitory GABAergic network in the vertebrate retina (20, 28-30). 
GABA-containing retinal neurons are horizontal cells, amacrine cells, 
interplexiform cells (an amacrine cell variant), bipolar cells and ganglion cells. The 
issue of whether horizontal cells can be generally considered as GABAergic is destined 
to remain unresolved. Indeed, they appear to contain GABA or GAD in some vertebrate 
retinas but not in others, with high variability also depending on the developmental time 
and the retinal location (see (29) for review). Small subsets of bipolar cells may contain 
GABA in a number of vertebrate retinas. In primates, for instance, there are conflicting 
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reports of the presence or the absence of GABA immunoreactivity in bipolar cells (see 
(31) for references). GABA-containing amacrine cells constitute one of the largest 
neuronal populations in the retina, and they account for 37-38% of the total amacrine 
cells in the rabbit retina (32). A number of subpopulations of GABA-containing 
amacrine and interplexiform cells can be identified on the basis of coexpressed 
transmitters/peptides (see (33, 34) for references). In the ganglion cell layer (GCL), both 
displaced amacrine cells and ganglion cells containing GABA have been reported (35). 
Three types of GABA receptors, with distinct structural and pharmacological 
characteristics, mediate inhibition in the retina: the ionotropic GABAA and GABAC 
receptors, and the metabotropic GABAB receptors (see (20) for review). Activation of 
these receptors leads to neuron hyperpolarization, with subsequent reduction of 
transmitter release and/or action potential firing. GABAA receptors are pentameric and 
consist of α, β, γ, and δ subunits. The pharmacology of these receptors may vary 
depending on the assembled subunits. The most common combination is α1/β2/γ2, 
which is widely expressed in the central nervous system, including the retina. These 
receptors are directly coupled with Cl
-
 channels, can be specifically blocked by 
bicuculline and have modulatory binding sites for benzodiazepines, barbiturates, ethanol 
and neurosteroids. GABAB receptors are G-protein-coupled receptors, with second 
messenger pathways leading to increase in K
+
 conductance, or decrease in voltage-
dependent Ca
2+
 currents. The GABAB receptor is activated by baclofen and it is 
insensitive to bicuculline. GABAC receptors are found predominantly in the retina. They 
are Cl
-
 pores, blocked by picrotoxin but  insensitive to bicuculline and baclofen. 
Structurally, GABAC receptors characteristically consist of ρ subunits, which form 
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homoligomeric channels with GABAC receptor pharmacology. All of these receptors 
are widely expressed in vertebrate retinas (20, 28). 
 
4. GABA uptake and GABA transporters in the retina 
 
High affinity GABA uptake systems in the retina mediate GABA accumulation into 
neurons, Müller cells and retinal pigment epithelium cells with complex kinetic and 
pharmacological properties (36). In different vertebrate retinas, the uptake of GABA or 
GABA analogs has been extensively used in the past to map the retinal GABAergic 
system (37-43). In rabbit retina, GABA, the GABA analog diaminobutyric acid 
(DABA), the GABA agonist isoguvacine and the GABA uptake blocker nipecotic acid 
are taken up into neurons and Müller cells, while the GABA analogs γ-vinyl GABA and 
gabaculine are selectively accumulated, respectively, in amacrine cells and Müller cells 
(44). These uptake patterns suggest that multiple GABA transporters operate in the 
retina. They do not seem to operate in horizontal cells of rabbit and rat retinas, as it has 
been demonstrated that these cells do not take up GABA or GABA analogs (42, 44-48). 
A variety of studies has established that there is a prominent expression of GATs in 
the retina. GAT-1, GAT-2 and GAT-3 mRNAs have been detected in rat retina using 
RT-PCR and Northern blot analysis (49, 50). Furthermore, they have been reported in 
developing and adult rat optic nerve by Northern blotting (51). GAT-1 is likely to be the 
principal GABA transporter in the retina (see below). GAT-2 do not seem to be 
expressed by cells of the neural retina. Indeed, GAT-2 immunoreactivity is 
predominantly distributed to the retinal pigment and ciliary epithelia  (52-54), congruent 
with findings that cultured bovine retinal pigment epithelia accumulate GABA (55). 
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GAT-3 mRNA has been detected mostly in the INL of rat retina by in situ hybridization 
(56). Immunocytochemical analyses showed that it is distributed to all retinal layers, 
with an expression pattern indicating that it is predominantly localized to Müller cells in 
rat, rabbit and guinea pig retinas (52-54, 57). In addition, GAT-3 is also expressed by a 
number of amacrine and displaced amacrine cells originating a dense plexus of GAT-3 
immunoreactive fibers in the IPL (53, 54, 57). 
 
5. Localization of GAT-1 in the retina 
 
After the cloning of GAT-1 from the rat brain (58), its expression in the rat retina, 
together with GAT-2 and GAT-3 expression, was first demonstrated with polymerase 
chain reaction analysis in 1992 (49). Subsequently, the presence of GAT-1 in retinas of 
other vertebrates has been investigated. For instance, a skate GABA transporter 
displaying high homology with the mouse GAT-1 has been detected by Northern blot in 
the skate retina (59), and GAT-1 immunoreactivity has been observed by immunoblot in 
goldfish retina (Klooster et al., 2004). In addition, studies of the uptake and release of 
GABA in the presence of the GAT-1 inhibitors nipecotic acid or NNC-711 provided 
evidence of the presence in chicken dissociated retinal cells in culture of a transporter 
with pharmacology similar, although not identical, to GAT-1 (60). The expression 
patterns of GAT-1 in the retina have been investigated with a variety of techniques and 
the presence of this transporter in selected retinal cell types has been reported. 
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5.1. GAT-1 in ganglion cells and/or displaced amacrine cells 
The GCL contains both ganglion cells and displaced amacrine cells. The ganglion cells 
are the output neurons of the retina, and with their axons contact the primary visual 
nuclei in the brain. In contrast, the displaced amacrine cells are similar to the normally 
placed amacrine cells in the INL, their processes arborize in the IPL and they do not exit 
the retina (61). Using immunohistochemistry or in situ hybridization histochemistry, 
GAT-1 has been found to be expressed by cells in the GCL in tiger salamander (62), 
salmon (63), rat (50, 53, 56, 64), mouse (65, 66), rabbit (67), bovine (68), and primate 
(31) retinas. In most cases, these cells displaying GAT-1 immunoreactivity or GAT-1 
mRNA have been interpreted as displaced amacrine cells mainly on the basis of the 
small soma size suggesting these cells were unlikely to be ganglion cells. However, 
retrograde transport of Fluorogold from the superior collicuclus combined with situ 
hybridization histochemistry demonstrated that at least a few of the GAT-1 mRNA 
expressing cells in the GCL of the rat retina are indeed ganglion cells (50). In addition, 
the observation of some GAT-1 immunostained fibers in the nerve fiber layer (NFL, 
which contains the ganglion cell axons) of the rabbit retina could indicate the presence 
of some GAT-1 expressing ganglion cells in the rabbit retina as well (67). This 
interpretation is not supported by observations in primate retinas, where GAT-1 
immunopositive fibers have been observed in the NFL, but they did not reach the optic 
nerve, suggesting they are not ganglion cell axons (31). Furthermore, in mouse retina 
retrograde tracing from the superior collicuclus fails to label neuropeptide Y (NPY)-
containing cells in the GCL, which also express GAT-1, indicating these cells are 
displaced amacrine cells (66). 
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Taken together, these data are consistent with the presence of GAT-1 in displaced 
amacrine cells, although a small number of ganglion cells may also express this 
transporter. The possibility also exists that a higher number of ganglion cells possess 
GAT-1. For instance, in primates GABA-immunoreactive ganglion cells and ganglion 
cell axons have been identified (69-72), but GAT-1-immunoreactive ganglion cells are 
unlikely (31). These GABA-containing ganglion cells, if they express GAT-1, are 
therefore likely to express it at their preterminal axonal processes and axonal terminals 
in retinal recipient nuclei, similar to the expression of GAT-1 on axonal terminals of 
hippocampal and cortical neurons (73, 74).  
 
5.2. GAT-1 in amacrine cells 
The majority of GAT-1-expressing cells in the retina are amacrine cells. The presence 
of GAT-1 in amacrine cells has been documented in most of the species studied to date 
(31, 50, 52-54, 56, 57, 62-68, 75-77), while in skate and bullfrog retinas strong GAT-1 
immunostaining is reported in the IPL (78, 79), which suggests the presence of GAT-1-
expressing amacrine cells. With immunohistochemical labeling, the IPL appears heavily 
GAT-1 immunostained, displaying intensely stained puncta and varicose processes. In 
some instances, GAT-1-immunolabeled somata have been reported within the IPL 
(interstitial amacrine cells) (31, 50). GAT-1-immunostained somata in the INL have 
often been observed to originate a process directed towards the OPL (31, 53, 54, 62, 
67), where a meshwork of GAT-1-immunoreactive fibers has been detected in the 
monkey (31) and in the rabbit (Casini G., Rickman D.W. and Brecha N.C., 
unpublished) retina. The cells originating these processes are known as interplexiform 
cells, which can be considered an amacrine cell variant. The typical pattern of GAT-1 
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expression is represented in figure 2, which depicts an immunolabeling of the mouse 
retina (G. Casini, unpublished). 
The predominant localization of GAT-1 to amacrine and interplexiform cells is 
generally congruent with the pattern of GABA- or GAD-containing cells and of GABA- 
or GABA analog-accumulating cells. Double label immunohistochemical studies have 
addressed the presence of GABA in GAT-1-expressing amacrine cells (Fig. 3). 
Colocalization of the two markers has been observed in amacrine cells of the goldfish 
retina (77), and quantitative data have been obtained in rabbit and in primate retinas. In 
one study of the rabbit retina, 99% of the GAT-1-immunoreactive amacrine cells were 
found to also contain GABA immunoreactivity, while 75% of the GABA-containing 
amacrine cells also expressed GAT-1 (67). Our unpublished observations in rabbit 
retina give an estimate of 66% of GABA-immunostained amacrine cells also displaying 
GAT-1 immunoreactivity (Casini G., Rickman D.W. and Brecha N.C., unpublished). 
Similar percentages (99% of GAT-1 amacrine cells also containing GABA and 66% of 
GABA-containing amacrine cells also displaying GAT-1) have been calculated in 
primate retinas (31). Since about 38% of all amacrine cells in rabbit retinas contain 
GABA (32), it follows that GAT-1 is expressed by 25-30% of all amacrine cells in these 
retinas. GABA-containing cells that do not express GAT-1 may take up GABA via 
another GAT, such as GAT-3, or they may lack a high-affinity GABA uptake system, 
similar to Purkinje cells of the cerebellum which do not express either GAT-1 or GAT-3 
(80). 
Interestingly, some GAT-1-expressing amacrine cells that do not contain GABA 
immunoreactivity have been reported in the rabbit retina (57). In particular, our 
quantitative studies of the rabbit retina (Casini G., Rickman D.W. and Brecha N.C., 
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unpublished) show that this subset of GAT-1 / no-GABA cells amounts to 6.7% of all 
GAT-1-expressing amacrine cells, and a portion of them is likely to be represented by 
glycinergic AII amacrine cells (Fig. 4). The presence of GAT-1 immunoreactivity in 
cells that do not contain GABA is consistent with other reports that GAT-1 mRNA and 
immunoreactivity are also localized to non-GABA immunoreactive cells in other parts 
of the nervous system (81). The expression of GAT-1 by a small percentage of AII 
amacrine cells may be the consequence of errors during retinal formation. Indeed, 
during the early part of postnatal retinal development, about 32% of the amacrine cells 
contain both GABA and glycine immunoreactivity (82), and it is plausible that a small 
number of the cells destined to become glycinergic may maintain some GABAergic, 
non-functional characteristics. 
Multiple subpopulations of GABA-containing amacrine cells have been detected in 
colocalization studies (33, 34), and the presence of GAT-1 in some of these 
subpopulations has also been tested. In the mouse retina, GAT-1 is expressed by the 
NPY-containing amacrine and displaced amacrine cells (66), while in monkey retina it 
is in vasoactive intestinal peptide (VIP)-containing amacrine cells (31). In contrast, 
GAT-1 immunoreactivity has not been reported in rabbit cholinergic amacrine cells (67) 
and in monkey dopaminergic amacrine cells (31). We have recently performed an 
extensive double-label quantitative immunohistochemical analysis of the composition 
of the population of GAT-1-expressing amacrine cells (Casini G., Rickman D.W. and 
Brecha N.C., unpublished). We found that the GAT-1-expressing amacrine cells include 
those containing VIP (Fig 5), those accumulating indoleamines and part of those 
containing substance P. In addition, about 20% of the GAT-1-immunoreactive amacrine 
cells also contain the calcium binding protein parvalbumin. GAT-1 immunostained 
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amacrine cells containing the calcium binding protein calbindin (CaBP) were also 
observed (Fig. 6). Together, these identified subgroups of amacrine cells account for 
57% of all GAT-1 immunoreactive amacrine cells. The remaining 43% are likely to be 
composed of other GABA-containing amacrine cell populations (Fig. 7). Consistent 
with previous observations in rabbit and in monkey retinas (31, 67), we did not observe 
GAT-1 expression in cholinergic or in dopaminergic amacrine cells. The possibility 
exists that GAT-1 is expressed on the processes these cells and not, or very rarely, on 
their cell bodies, as it may be the case for some ganglion cells (see paragraph 5.1). 
 
5.3. GAT-1 in bipolar cells 
GAT-1-expressing bipolar cells have been demonstrated in tiger salamander retinas, 
where immunohistochemical studies have reported GAT-1 immunoreactivity in two 
different types of bipolar cells which also contained GABA (62). In addition, whole cell 
patch recordings from these cells revealed the presence of a GAT current (IGAT) that was 
blocked by NO-711 (83), a selective GAT-1 antagonist (19). In contrast, bipolar cells 
expressing GAT-1 have not been reported in other vertebrate retinas. In particular, lack 
of colocalization of the immunoreactivities of GAT-1 and of a generic bipolar cell 
marker has been recently reported in the monkey retina (31). 
 
5.4. GAT-1 in horizontal cells 
In the retina of several vertebrate species, GABA is used by horizontal cells as a 
neurotransmitter (29). However, GAT-1 has not been localized to horizontal cells with 
in situ or immunohistochemical methods. For instance, horizontal cells identified by 
CaBP immunoreactivity in the rabbit retina are devoid of GAT-1 immunostaining 
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(Casini G., Rickman D.W. and Brecha N.C., unpublished, Fig. 6). Only in non-
mammalian retinas there is electrophysiological and pharmacological evidence of 
electrogenic GABA transport mechanisms consistent with the presence of GAT-1 in 
horizontal cells. Indeed, IGATS elicited by GABA uptake and/or release through a 
transporter have been detected in skate, catfish, goldfish, toad and tiger salamander 
horizontal cells, and these currents were sensitive to selective inhibitors of GABA 
transport through GAT-1, such as nipecotic acid, NO-711 or SKF89976A (84-92). 
The lack of GAT-1 expression in mammalian horizontal cells is congruent with 
studies showing that these cells do not accumulate exogenous GABA or GABA analogs 
(42, 44-48), and that they also lack GAT-1 or GAT-3 expression (50, 53, 54, 57). 
However, horizontal cells in several mammalian species express GABA and GAD (93), 
suggesting that horizontal cells possess the machinery to synthesize and release GABA, 
but they do not have the cellular mechanisms to take up GABA from the extracellular 
space, similar to the Purkinje cell of the cerebellum (80). We may hypothesize that in 
these cases GABA released in the OPL could be transported from the extracellular 
space by GAT-1 located on processes of interplexiform cells or by GAT-3 expressed by 
Müller cells. 
 
5.5. GAT-1 in Müller cells 
A highly efficient GABA uptake system by Müller cells has been described in the 
guinea pig retina, where both GAT-1 and GAT-3 are expressed by Müller cells (54). In 
addition, the presence of GAT-1 in Müller cells of the rat retina has been demonstrated 
with in situ hybridization (50) and immunohistochemistry (53). GAT-1, however, is 
only weakly expressed by these cells, which instead show a prominent GAT-3 
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expression (50, 53). In non-mammalian retinas, both GAT-1 and GAT-3 have been 
immunohistochemically detected in Müller cells of the skate retina (78), while Müller 
cells of the bullfrog retina have been found to express GAT-1 and GAT-2 
immunoreactivities, while they do not express GAT-3 (79). 
 
5.6. Summary of the localization of GAT-1 in the retina 
Taken together, the data presented above show that GAT-1 is abundantly expressed in 
vertebrate retinas. Overall, the distribution of GAT-1 in the retina is similar to the 
distribution of GABA and GAD immunoreactivities, and of GABA or GABA analogue 
uptake. GAT-1-expressing cells are mainly amacrine cells, including displaced and 
interstitial amacrine cells, and interplexiform cells. A few ganglion cells may also 
express this transporter, while it is not expressed by photoreceptors. 
Different subpopulations of GAT-1-immunoreactive amacrine cells have been 
identified, and many GABA-containing amacrine cells that do not express GAT-1 have 
also been detected. These cells could express other GATs, such as GAT-3, or they could 
express GAT-1 on their processes but not on their cell bodies. 
In mammalian retinas, GAT-1 is not expressed by horizontal or bipolar cells. The 
pattern of GAT-1 expression in mammalian retinas is consistent among mice, rats, 
guinea pigs, rabbits and primates, with the only exception that in rats and guinea pigs 
GAT-1 is weakly expressed in Müller cells, whereas it is not expressed in Müller cells 
of rabbits and primates. 
The absence of GABA uptake systems in horizontal cells of mammalian retinas 
raises the question of how GABA can be removed from the outer retina. The possibility 
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exists that this function is operated by GAT-1 expressed on the distal processes of 
interplexiform cells and/or by GAT-1 and, mainly, GAT-3 expressed by Müller cells. 
In non-mammalian retinas, similar patterns of GAT-1 distribution have been 
reported, with the notable exceptions of the presence of GAT-1 in horizontal cells and, 
at least in the case of the tiger salamander retina, in bipolar cells. 
 
6. Functions of GAT-1 in the retina 
 
6.1. Both GAT-1 and GAT-3 regulate GABA levels in the retina 
The inhibition of GABA uptake mediated by GAT-1 in different regions of the central 
nervous system, including the retina, invariably results in increased tonic inhibition, 
suggesting that this transporter is a key player in the regulation of GABA 
neurotransmission. The widespread distribution of GAT-1 and GAT-3 in the retina 
indicates the presence of careful regulation of GABAergic signaling in the retina. For 
instance, GAT-1 and GAT-3 expressed by Müller cells would markedly influence 
GABA levels in all retinal regions, both by regulating GABA in the extracellular space 
and by limiting the spread of GABA from synapses (94). Moreover, the GATs 
expressed by Müller cells may protect the synapses from inappropriate inhibition by 
excess GABA released elsewhere during physiological and/or pathological events. 
The characteristic morphology of Müller cells, which span the entire neural retina, 
enables these cells to influence GABAergic transmission both in the outer and in the 
inner retina, by taking up GABA released by horizontal cells and by amacrine cells, 
respectively. In contrast, GATs expressed by neurons are likely to both remove GABA 
from the synaptic cleft following depolarization and release GABA by reversed 
G. Casini 
 19 
transport. Indeed, there is good evidence for carrier-mediated release of GABA by non-
mammalian horizontal cells (84, 86, 91) and by the acetylcholine- and GABA-
containing starburst amacrine cells of the rabbit retina following depolarization (95). 
In summary, GAT-1, expressed by neurons, is likely to be involved in GABA 
removal from the synaptic cleft and extracellular space and perhaps in GABA release by 
a Ca
2+
-independent mechanism, thus modulating GABA levels and GABA actions at 
GABA receptors. GAT-1 and GAT-3 expressed by Müller cells could also influence the 
levels of GABA, acting both in the inner and in the outer retina, and probably limit the 
spread of GABA within the retina. GAT-1 and GAT-3 have different functional and 
pharmacological properties, including different ionic dependences and inhibitor 
sensitivities, that influence GABA uptake. This pharmacological and functional 
heterogeneity is likely to provide considerable flexibility in the control of the 
extracellular levels of GABA in different physiological states. 
 
6.2. Regulation of GABA receptor activation by GAT-1 at retinal synapses 
The transmission of the visual signal from bipolar cells to ganglion cells is influenced 
by GABAC receptors located on the bipolar cell axon terminals and by GABAA 
receptors located both on bipolar cell terminals and postsynaptic to the bipolar cell, on 
amacrine and ganglion cell dendrites (28). The activation of GABAC receptors 
importantly contributes to the regulation of bipolar cell output, and dysfunctions in 
GABAC receptor function result in altered ganglion cell responses (see (96) for 
references). The available evidence suggests that GABAC receptors may act to limit the 
extent of glutamate release from bipolar cell terminals. In the salamander retina, the 
selective GAT-1 blocker NO-711 determines an increase of the activation of GABAC 
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receptors, with consequent reduction of the light-elicited signaling from bipolar cells to 
ganglion cells. This enhanced GABAC-mediated response is likely to be due to 
activation of additional receptors by GABA spillover (97). The suppression of bipolar 
cell to ganglion cell transmission, provoked by GAT-1 blockade, affects the ganglion 
cell responses in a way similar to the reported effect of surround inhibition. These 
observations suggest that GAT-1 normally limits inhibitory signaling acting particularly 
at GABAC receptors. If GAT-1 were non-functional, additional GABAC receptors 
would be activated by spillover transmission, with consequent impairment of both the 
spatial and temporal properties of ganglion cell responses. 
Recently, recordings from isolated bipolar cell terminals in goldfish retinal slices 
have shown that a tonic current mediated by GABAC receptors is maintained by 
spontaneous GABA release and that the level of this current is tightly regulated by 
GAT-1. In addition, GAT-1 selectively limits the GABAC receptor-mediated reciprocal 
feedback between bipolar cell terminals and amacrine cells (96). These observations 
implicate that GAT-1 is a major regulator of presynaptic excitability at the bipolar cell 
axonal terminal by setting the concentration of extracellular GABA in the vicinity of 
bipolar cell GABAC receptors. Supporting this conclusion, GAT-1 inhibition 
significantly increases the amount of current necessary to depolarize the bipolar cell 
terminal to its threshold for generating action potentials (96).  
  
6.3. Effects of GAT-1 blockade on electroretinographic responses 
In a recent study, the administration of the GAT-1 blocker NO-711 determined a 
pronounced increase of the b-wave of electroretinographic responses from isolated 
rabbit retinas (98). An explanation for this effect, proposed by the authors, is that as a 
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consequence of the reduced GABA uptake, amacrine cells would become depleted of 
their GABA content, and their release of GABA upon light stimulation would be 
reduced. Therefore, the inhibition mediated by GABA receptors on the ON-bipolar cell 
axonal terminals would also be reduced, and this would cause the increase of ON-
bipolar cell activity and the enlargement of the b-wave, which can increase to double its 
normal size.  
 
6.4. GAT-1 and retinal development 
In adult retinas, GABA is predominantly expressed by amacrine cells. During 
development, GABA is transiently expressed in additional cells, including ganglion and 
horizontal cells. GABA uptake and release mechanisms and GABA receptors are also 
expressed early in retinal development, well in advance of the onset of visual function. 
In addition, GABA transporter mRNAs have been detected in the developing rat optic 
nerve (51). These observations suggest that the GABAergic system may serve a 
developmental role both in the establishment of retinal circuitries and in the 
organization of retinofugal projections (44, 99). The GABA transporter is likely to play 
extremely important roles, because it seems to be responsible for GABA release, 
through reversed transport, early in development, prior to the establishment of vesicular 
synaptic transmission (99).  
Spontaneous activity during development is essential for proper differentiation and 
refinement of the nervous system. In the retina such activity takes the form of rhythmic 
waves of intracellular [Ca
2+
] elevations (100).  Recent observations have shown that 
endogenous GABA can modulate the frequency and the duration of such waves in the 
chick retina. This effect is mediated by GABAB receptors in a cAMP-independent 
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manner, and this action is influenced by GAT-1. In particular, it has been observed that 
the GAT-1 inhibitor SKF89976A reduces the frequency of the transients presumably 
because it induces an increase in the extracellular concentration of GABA (101). 
 
6.5. Summary of the functions of GAT-1 in the retina 
The experimental data reported in this section demonstrate that GABA transporters, and 
GAT-1 in particular, may affect multiple retinal functions, including important aspects 
of retinal development, by regulating extracellular levels of GABA. By modulating the 
availability of GABA in the extracellular milieu and/or at specific synapses, GAT-1 and 
GAT-3 determine the overall level of inhibition in the retina or the amount of inhibitory 
signal at specific synapses. Mainly interacting with GABAC receptors, GAT-1 
contributes to the shaping of ganglion cell responses, and interacting with GABAB 
receptors, this transporter is likely to play important developmental functions. Other 
important functional actions are exerted through GABA release mediated by GAT-1 
reversed transport. These include GABA release by cholinergic/GABAergic starburst 
amacrine cells and GABA release during early retinal development. 
 
7. Anti-epileptic drugs, retinal GABA and GAT-1 
 
Anti-epileptic drugs have been developed with the aim of contrasting excess excitation 
by increasing GABAergic inhibition in the central nervous system. Two recently 
developed compounds, vigabatrin and tiagabin, increase GABA availability through two 
different mechanisms. Vigabatrin attenuates GABA metabolism by inhibiting the 
enzyme GABA-transaminase, whereas tiagabine blocks GABA uptake by GAT-1. As 
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part of the central nervous system, the retina is also affected by treatment with these 
molecules. Vigabatrin accumulates in the retina and induces a greater increase of 
GABA concentrations in the retina than in the brain. These abnormally high GABA 
levels in the retina often result in significant visual field constriction. In contrast, 
tiagabine does not accumulate in the retina, it does not over-inhibits GAT-1 and does 
not cause visual field disturbances (102). These observations indicate that interventions 
on the GABAergic system with anti-epileptic purposes should privilege the compounds, 
like tiagabine, directed at inhibiting GABA uptake, since these compounds do not seem 
to significantly impair visual function. 
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Table 1 – Nomenclature and principal characteristics of GATs 
 
Mouse 
nomenclature 
Rat / Human 
nomenclature 
Characteristic inhibitors 
Localization in the central 
nervous system 
GAT1 GAT-1 ACHC, tiagabine 
Axon terminals; a few 
astrocytic processes 
GAT2 BGT-1 betaine Astrocytes  
GAT3 GAT-2 β-alanine 
Neuronal and non-neuronal 
elements (low expression) 
GAT4 GAT-3 β-alanine Distal astrocytic processes 
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Figure legends 
 
Figure 1. Schematic representation of the vertebrate retina. Visual information passes 
from photoreceptors to bipolar cells (BC) through synapses in the outer 
plexiform layer (OPL). Horizontal cells provide inhibitory regulation of this 
flow, although there is uncertainty about the involvement of GABA. In the inner 
plexiform layer (IPL), bipolar cell axonal terminals contact ganglion cell (GC) 
dendrites. Here, prominent inhibitory actions provided by GABAergic amacrine 
cells (AC) importantly contribute to the physiological responses of ganglion 
cells, whose axons reach the retino-recipient nuclei in the brain. Other 
abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; NFL, nerve 
fiber layer; ONL, outer nuclear layer; POS, photoreceptor outer segments. 
 
Figure 2. Pattern of GAT-1 immunoreactivity in the mouse retina. Immunofluorescent 
somata are mainly amacrine cells located in the proximal INL. Processes of 
GAT-1 immunolabeled interplexiform cells arise from the immunoreactive fiber 
plexus in the IPL or from immunostained cell bodies in the INL (arrows) and 
arborize in the OPL. Displaced amacrine cells in the GCL can also be seen. 
GAT-1 immunoreactive processes are densely distributed in the IPL, with 
heavier labeling in the distal and in the proximal part of the layer. 
Paraformaldehyde-fixed cryostat section (10 μm thick). Immunofluorescence 
obtained with a rabbit primary antibody directed to GAT-1 (Chemicon) and a 
secondary goat anti-rabbit antibody conjugated with Alexa Fluor 488 (Molecular 
Probes). Abbreviations as in figure 1. Calibration bar, 50 μm. 
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Figure 3. Pattern of GAT-1 and GABA colocalization in the rabbit retina. A, GAT-1 
immunostaining; B, GABA immunostaining; C, overlay image of A and B. Note 
that some GAT-1-expressing amacrine cells are also GABA-immunolabeled 
(arrows), while there are GABA-containing somata which do not express GAT-1 
(asterisks). A GAT-1-expressing amacrine cell which does not contain GABA is 
also visible (arrowhead). GAT-1 immunostaining as in figure 2; the GABA 
antibody (Sigma) was made in mouse and visualized with goat anti-mouse 
secondary antibody conjugated with Alexa Fluor 546 (Molecular probes). 
Abbreviations as in figure 1. Calibration bar, 20 μm. 
 
Figure 4. GAT-1 and parvalbumin colocalization in the rabbit retina. A, GAT-1 
immunostaining; B, parvalbumin immunostaining; C, overlay image of A and B. 
Parvalbumin antibodies label two different populations of amacrine cells in the 
rabbit retina, including a class of unidentified GABA-containing amacrine cells 
and the population of glycinergic AII amacrine cells. Here, two cells with the 
typical morphology of AII amacrine cells can be seen to display GAT-1 
immunoreactivity at or near their plasma membrane (arrows). The parvalbumin 
antibody (Sigma) was made in mouse and visualized with goat anti-mouse 
secondary antibody conjugated with Alexa Fluor 546. Abbreviations as in figure 
1. Calibration bar, 20 μm. 
 
Figure 5. GAT-1 and VIP colocalization in the rabbit retina. A, GAT-1 immunostaining; 
B, VIP immunostaining; C, overlay image of A and B. All the VIP-containing 
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amacrine cells also express GAT-1 immunoreactivity (arrow). The VIP antibody 
(from H. Wong and Dr. J.H. Walsh, UCLA) was made in mouse and visualized 
with goat anti-mouse secondary antibody conjugated with Alexa Fluor 546. 
Abbreviations as in figure 1. Calibration bar, 20 μm. 
 
Figure 6. GAT-1 and CaBP colocalization in the rabbit retina. A, GAT-1 
immunostaining; B, CaBP immunostaining; C, overlay image of A and B. None 
of the CaBP-immunostained horizontal cells, near the OPL, display GAT-1 
immunoreactivity. In contrast, some of the CaBP-containing amacrine cells also 
express GAT-1 (arrow). The CaBP antibody (Sigma) was made in mouse and 
visualized with goat anti-mouse secondary antibody conjugated with Alexa 
Fluor 546. Abbreviations as in figure 1. Calibration bar, 20 μm. 
 
Figure 7. Diagram summarizing the composition of the population of GAT-1 
immunoreactive amacrine cells in the rabbit retina. 43% of these cells are 
unidentified GABA-containing amacrine cells, while 38% is represented by 
identified subsets of GABA-containing amacrine cells, including all 
indoleamine-accumulating and VIP-containing amacrine cells,  and some of the 
substance P (SP)-containing amacrine cells. In addition, 15% of the GAT-1-
immunoreactive amacrine cells contain PVA immunoreactivity and are 
presumably GABAergic as well. Finally, 4% of the GAT-1 immunoreactive 
amacrine cells are likely to be AII amacrine cells. 
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